BR0214060A - Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática - Google Patents

Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática

Info

Publication number
BR0214060A
BR0214060A BR0214060-8A BR0214060A BR0214060A BR 0214060 A BR0214060 A BR 0214060A BR 0214060 A BR0214060 A BR 0214060A BR 0214060 A BR0214060 A BR 0214060A
Authority
BR
Brazil
Prior art keywords
neuropathic pain
affective
monohydroxycarbamazepine
attention disorder
attention
Prior art date
Application number
BR0214060-8A
Other languages
English (en)
Inventor
Markus Schmutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127177A external-priority patent/GB0127177D0/en
Priority claimed from GB0127176A external-priority patent/GB0127176D0/en
Priority claimed from GB0127178A external-priority patent/GB0127178D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0214060A publication Critical patent/BR0214060A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

"USO DE MONOIDROXICARBAMAZEPINA EM DISTúRBIO AFETIVO E DE ATENçãO E DOR NEUROPáTICA". A invenção refere-se ao uso de um derivado de carbamazepina para o tratamento de distúrbios afetivos e da atenção, dor neuropática e distúrbios relacionados com dor neuropática.
BR0214060-8A 2001-11-12 2002-11-11 Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática BR0214060A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0127177A GB0127177D0 (en) 2001-11-12 2001-11-12 Organic compounds
GB0127176A GB0127176D0 (en) 2001-11-12 2001-11-12 Organic compounds
GB0127178A GB0127178D0 (en) 2001-11-12 2001-11-12 Organic compounds
PCT/EP2002/012578 WO2003042182A1 (en) 2001-11-12 2002-11-11 Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain

Publications (1)

Publication Number Publication Date
BR0214060A true BR0214060A (pt) 2004-10-13

Family

ID=27256320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214060-8A BR0214060A (pt) 2001-11-12 2002-11-11 Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática

Country Status (21)

Country Link
US (1) US20050004102A1 (pt)
EP (2) EP2048135A1 (pt)
JP (1) JP2005511623A (pt)
KR (1) KR20050044396A (pt)
CN (1) CN100506797C (pt)
AT (1) ATE408602T1 (pt)
AU (2) AU2007201925B2 (pt)
BR (1) BR0214060A (pt)
CA (1) CA2463970A1 (pt)
DE (1) DE60228988D1 (pt)
ES (1) ES2314111T3 (pt)
HK (1) HK1068350A1 (pt)
HU (1) HUP0402381A3 (pt)
IL (1) IL161700A0 (pt)
MX (1) MXPA04004470A (pt)
NO (1) NO20041955L (pt)
NZ (1) NZ556026A (pt)
PL (1) PL368591A1 (pt)
PT (1) PT1446383E (pt)
TW (1) TW200300090A (pt)
WO (1) WO2003042182A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
MXPA05008729A (es) * 2003-02-17 2005-09-20 Novartis Ag Uso de s-10-hidroxi-10, 11-dihidro-carbamazepina para el tratamiento de ansiedad y trastornos bipolares.
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
GB0307860D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006121363A1 (en) * 2005-05-06 2006-11-16 Portela & C.A., S.A. Eslicarbazepine acetate and methods of use
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505101A (de) 1969-03-31 1971-03-31 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso

Also Published As

Publication number Publication date
WO2003042182A1 (en) 2003-05-22
EP1446383B1 (en) 2008-09-17
HUP0402381A3 (en) 2008-01-28
ES2314111T3 (es) 2009-03-16
IL161700A0 (en) 2004-09-27
DE60228988D1 (de) 2008-10-30
KR20050044396A (ko) 2005-05-12
US20050004102A1 (en) 2005-01-06
NO20041955L (no) 2004-05-12
PT1446383E (pt) 2008-12-29
ATE408602T1 (de) 2008-10-15
AU2009201388A1 (en) 2009-05-07
EP1446383A1 (en) 2004-08-18
MXPA04004470A (es) 2005-05-16
JP2005511623A (ja) 2005-04-28
NZ556026A (en) 2008-06-30
CA2463970A1 (en) 2003-05-22
CN1585753A (zh) 2005-02-23
AU2007201925A1 (en) 2007-05-24
HK1068350A1 (en) 2005-04-29
HUP0402381A2 (hu) 2005-03-29
EP2048135A1 (en) 2009-04-15
CN100506797C (zh) 2009-07-01
TW200300090A (en) 2003-05-16
PL368591A1 (en) 2005-04-04
AU2007201925B2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
BR0009480A (pt) Soluções de poliuretano com unidades de estrutura de alcoxissilano
DK0888325T3 (da) Cykliske aminosyrer som farmaceutiske midler
PT1339399E (pt) Combinacoes de drogas (e.g., clorpromazina e pentamidina) para o tratamento de desordens neoplasicas
CL2010000018A1 (es) Fragmentos de peptido amiloide beta(ab) ab 1-7 y ab 3-7 ligados a un peptido portador, composicion farmaceutica que lo comprende y su uso para tratar la enfermedad de alzheimer
DK0705099T3 (da) Anvendelse af modafinil til behandling af søvnapnø og åndedrætslidelser af central oprindelse
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
BR0114344A (pt) Retinóides para o tratamento de enfisema
PT946157E (pt) Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular
BR0006971B1 (pt) vibrador de massagem para alÍvio de doloridos e dor.
BR0214060A (pt) Uso de monoidroxicarbamazepina em distúrbio afetivo e de atenção e dor neuropática
TR200402275T2 (tr) Nörotik düzensizliklerin tedavisi
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
PT1286986E (pt) Derivados de quinolil-piperidin-4-ilideno-metil-benzamida para o tratamento da dor
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
BR0115983A (pt) Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
BR0309684A (pt) O tratamento de dor com ifendropil
BR9810387A (pt) (s) 3, 4, 5-trimetoxibenzoato de 2-metilamino-2-fenil-n-butila, e sua aplicação para o tratamento de dor crÈnica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012.